Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

ABSTRACT:

Background

Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk.

Objective

To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss postmarketing experience outside clinical trials.

Methods

CAMMS223 and Comparison of Alemtuzumab and Rebif^® Efficacy in Multiple Sclerosis (CARE-MS) I and II investigated two annual courses of alemtuzumab 12 mg (or 24 mg in CAMMS223/CARE-MS II) versus subcutaneous interferon beta-1a three times per week. Patients completing core studies could enroll in an extension. Monthly monitoring for ITP continued until 48 months after the last alemtuzumab infusion.

Results<

SUBMITTER: Cuker A 

PROVIDER: S-EPMC6950888 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature